Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;6(7):1242-1262.
doi: 10.1038/s43018-025-00987-2. Epub 2025 Jun 27.

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features

Affiliations

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features

Ilaria Iacobucci et al. Nat Cancer. 2025 Jul.

Abstract

Developmental origins and their associations with lineage plasticity and treatment response in B-cell progenitor acute lymphoblastic leukemia (B-ALL) are mostly unexplored. Here, we integrated single-cell transcriptome sequencing (scRNA-seq) of 89 B-ALL samples with a single-cell atlas of normal human B cell development incorporating functional and molecular assays. We observed subtype- and sample-dependent correlation with normal developmental stage, with intra-subtype and intra-patient heterogeneity. We show that subtypes prone to shift from the B-lineage (for example BCR::ABL1, KMT2A-R and DUX4-R B-ALL) are enriched for multipotent progenitors and show this developmental stage exhibits CEBPA activation and retains myeloid potential, providing a mechanistic explanation for this clinical observation. We developed a 'multipotency score' most enriched in subtypes exhibiting lineage plasticity that was independently associated with inferior survival. Thus, multipotent B-ALL states reflect the early progenitor origins of a subset of patients with B-ALL and may be relevant for understanding lineage shifting following conventional chemotherapy or immunotherapies.

PubMed Disclaimer

Conflict of interest statement

Competing interests: I.I. reports consultation honoraria from Arima and travel expenses reimbursed by Mission Bio and Takara for invited talks. C.G.M. received research funding from AbbVie and Pfizer, honoraria from Amgen and Illumina, and royalty payments from Cyrus. He is on an advisory board for Illumina. J.E.D. received research funding from BMS/Celgene and intellectual property licenses from Pfizer/Trillium Therapeutics. A.S.A. reported advisory board membership for Nkarta, Pfizer, Novartis and Jazz Pharmaceuticals; honoraria from KSA, PER, MD Education, ALF Medscape/Global Activity, Web med, Onc live AML Geronimo; steering committee membership for Glycomimetics; and royalty payments from Springer. The other authors declare no competing interests.

Update of

References

    1. Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200–1228 (2022). - PMC - PubMed
    1. Alaggio R, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36, 1720–1748 (2022). - PMC - PubMed
    1. Duncavage EJ, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood 140, 2228–2247 (2022). - PMC - PubMed
    1. Iacobucci I, Kimura S & Mullighan CG Biologic and Therapeutic Implications of Genomic Alterations in Acute Lymphoblastic Leukemia. J Clin Med 10(2021). - PMC - PubMed
    1. Brady SW, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet 54, 1376–1389 (2022). - PMC - PubMed

MeSH terms

LinkOut - more resources